Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 17, 2017. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It strictly reports on specific share transactions.
| Transaction Date | Instrument | Price per Share | Volume | Transaction Type |
|---|---|---|---|---|
| July 14, 2017 | Ordinary Shares (25p each) | £16.0498 | 21 | Acquisition (Dividend Re-investment) |
| July 14, 2017 | Ordinary Shares (25p each) | £16.0498 | 18 | Acquisition (Dividend Re-investment) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by executives following the re-investment of dividends paid on July 13, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific insider trading activity.
Key Facts for Investor Verification
- Executives Involved: Mr. D S Redfern (Chief Strategy Officer) and Mrs. V A Whyte (Company Secretary).
- Transaction Nature: Both transactions were acquisitions of ordinary shares via dividend re-investment plans (DRIP) within Individual Savings Accounts (ISAs).
- Market Data: Shares were acquired on the London Stock Exchange (XLON) at a price of £16.0498 per share.
- Volume: Mr. Redfern acquired 21 shares; Mrs. Whyte acquired 18 shares.